Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
Top Page
Lincoln Pharmaceuticals Ltd
(LINCOLN)
Select Model
Select Model
Rating:78Outperform
Price Target:
₹696.00
▲(40.15% Upside)
Action:ReiteratedDate:02/11/26
The score is primarily supported by strong financial performance, especially the near-debt-free balance sheet and resilient profitability, tempered by margin compression and some cash-flow variability. Technicals are constructive but somewhat overextended and not yet above the 200-day average. Valuation is reasonable on earnings, though the dividend yield is minimal.
Positive Factors
Balance Sheet Strength
An effectively debt-free balance sheet gives Lincoln durable financial flexibility: it can fund capex, R&D, or bolt-on deals without relying on external financing, absorb cyclical downturns with low solvency risk, and keep interest costs minimal—supporting long-term strategic optionality.
Negative Factors
Margin Compression
Noticeable margin deterioration reflects rising cost pressures or pricing challenges that reduce earnings power. Sustained margin compression can erode cash flow and ROE, constrain reinvestment capacity, and require either efficiency measures or pricing resets to restore prior profitability levels.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
An effectively debt-free balance sheet gives Lincoln durable financial flexibility: it can fund capex, R&D, or bolt-on deals without relying on external financing, absorb cyclical downturns with low solvency risk, and keep interest costs minimal—supporting long-term strategic optionality.
Read all positive factors
Lincoln Pharmaceuticals Ltd (LINCOLN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹11.01B
Dividend Yield0.37%
Average Volume (3M)1.66K
Price to Earnings (P/E)8.5
Beta (1Y)1.33
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees1,687
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)14.28
Shares Outstanding20,029,728
10 Day Avg. Volume3,133
30 Day Avg. Volume1,664
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.65
Price to Sales (P/S)1.77
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72
Revenue Forecast (FY)₹8.82B
Lincoln Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, oto...
How the Company Makes Money
Lincoln Pharmaceuticals makes money primarily by selling pharmaceutical products (finished-dose formulations) to customers in India and in overseas markets. Revenue is generated from (1) domestic sales through its marketing and distribution networ...
Lincoln Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.32B | 6.23B | 5.81B | 5.05B | 4.68B | 4.15B |
| Gross Profit | 3.03B | 3.32B | 2.97B | 2.59B | 2.46B | 2.13B |
| EBITDA | 1.24B | 1.24B | 1.34B | 1.12B | 1.05B | 928.43M |
| Net Income | 800.04M | 823.46M | 933.05M | 728.99M | 693.55M | 622.50M |
Balance Sheet | ||||||
| Total Assets | 8.55B | 7.97B | 7.00B | 5.87B | 5.34B | 4.52B |
| Cash, Cash Equivalents and Short-Term Investments | 2.32B | 1.96B | 1.52B | 1.14B | 1.15B | 945.06M |
| Total Debt | 668.00K | 0.00 | 10.67M | 19.97M | 20.44M | 5.20M |
| Total Liabilities | 1.39B | 1.25B | 1.07B | 849.46M | 1.01B | 859.67M |
| Stockholders Equity | 7.16B | 6.72B | 5.93B | 5.02B | 4.33B | 3.66B |
Cash Flow | ||||||
| Free Cash Flow | 390.02M | 737.71M | 237.41M | 249.80M | 306.07M | 605.19M |
| Operating Cash Flow | 497.63M | 930.15M | 632.17M | 392.62M | 761.32M | 692.70M |
| Investing Cash Flow | -422.12M | -789.47M | -573.42M | -366.43M | -780.80M | -642.27M |
| Financing Cash Flow | -6.86M | -64.02M | -51.80M | -45.01M | -25.56M | -57.45M |
Lincoln Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹11.01B | 8.47 | ― | 0.37% | ― | ― | |
64 Neutral | ₹6.50B | 19.44 | ― | 1.96% | -6.96% | -66.75% | |
64 Neutral | ₹7.90B | 12.53 | ― | ― | 8.92% | -5.56% | |
62 Neutral | ₹7.34B | 14.99 | ― | 1.92% | 14.09% | -34.41% | |
60 Neutral | ₹7.33B | 22.95 | ― | 0.48% | -18.86% | -150.92% | |
56 Neutral | ₹4.59B | 34.53 | ― | ― | 32.95% | 67.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
549.45
-0.93
-0.17%
IN:KILITCH
Kilitch Drugs (India) Limited
131.30
-37.51
-22.22%
IN:KOPRAN
Kopran Limited
134.55
-51.77
-27.79%
IN:THEMISMED
Themis Medicare Limited
79.60
-42.95
-35.05%
IN:WANBURY
Wanbury Limited
226.05
-12.70
-5.32%
IN:ANUHPHR
Anuh Pharma Limited
73.28
-11.20
-13.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.